Results 71 to 80 of about 30,950 (253)

Therapeutic decision-making for patients with fluctuating mitral regurgitation [PDF]

, 2015
Mitral regurgitation (MR) is a common, progressive, and difficult-to-manage disease. MR is dynamic in nature, with physiological fluctuations occurring in response to various stimuli such as exercise and ischaemia, which can precipitate the development ...
A Auricchio, A Gisbert, A Tenenbaum, AP Lee, C Ypenburg, C Ypenburg, CM Yu, DH Kang, DJ LaPar, EA Grossi, F Bursi, F Grigioni, F Lebrun, F Maisano, G Keren, G Tumminello, Giovanni La Canna, H Kanzaki, J Braun, J Hung, J Madaric, J Magne, J Magne, J Magne, J Magne, J Raman, J Schofer, JL Zamorano, K Fattouch, K Fattouch, K Fattouch, K Fattouch, K Kusunose, K Yared, Khalil Fattouch, KMJ Chan, L Aklog, L Perez de Isla, LA Piérard, LA Piérard, LB Rosario, M De Bonis, M Izumo, M Moonen, M Sénéchal, MA Acker, MD Tischler, MG Sutton, MH Picard, P Lancellotti, P Lancellotti, P Lancellotti, P Lancellotti, P Lancellotti, P Lancellotti, P Lancellotti, P Lancellotti, P Lancellotti, Patrizio Lancellotti, PW Fedak, R Lorusso, RA Levine, RA Nishimura, S Gelsomino, S Sack, S Sponga, SF Bolling, T Feldman, T Feldman, T Feldman, T Siminiak, TA Timek, TH Marwick   +72 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Relationship between severity of mitral regurgitation and renal function in patients with ischemic chronic heart failure

Zaporožskij Medicinskij Žurnal, 2015
Mitral regurgitation (MR) - frequent complication of prolonged and severe coronary artery disease, left ventricular systolic dysfunction (LV) of different genesis and plays an important role in the onset and progression of chronic heart failure (CHF).
D. A. Lashkul
doaj   +1 more source

Echocardiographic assessment of ischemic mitral regurgitation [PDF]

Cardiovascular Ultrasound, 2014
Ischemic mitral regurgitation is an important consequence of LV remodeling after myocardial infarction. Echocardiographic diagnosis and assessment of ischemic mitral regurgitation are critical to gauge its adverse effects on prognosis and to attempt to tailor rational treatment strategy.
Dudzinski, David M, Hung, Judy
openaire   +2 more sources

Pattern of Cardiovascular Diseases Among Elderly Patients Admitted in Medical Wards at Muhimbili National Hospital Dar es salaam Tanzania [PDF]

, 2011
Cardiovascular disease is the most frequent cause of death in persons over the age 50 years and most importantly it is responsible for considerable morbidity and large burden of disability in the community. Cardiovascular diseases are an increasing cause
Kisenge, Peter Richard
core  

Residual mitral regurgitation after repair for posterior leaflet prolapse- Importance of preoperative anterior leaflet tethering [PDF]

, 2018
Background Carpentier's techniques for degenerative posterior mitral leaflet prolapse have been established with excellent long‐term results reported. However, residual mitral regurgitation ( MR
Chikazawa, Genta, Hayashida, Akihiro, Hiraoka, Arudo, Kagiyama, Nobuyuki, Sakaguchi, Taichi, Tamura, Kentaro, Toki, Misako, Totsugawa, Toshinori, Yoshida, Kiyoshi, Yoshitaka, Hidenori   +9 more
core   +2 more sources

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment. [PDF]

, 2010
peer reviewedIschaemic mitral regurgitation is a frequent complication of left ventricular global or regional pathological remodelling due to chronic coronary artery disease. It is not a valve disease but represents the valvular consequences of increased
Carabello, B. A., PIERARD, Luc
core   +1 more source

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source